DKD patients have predominantly received treatment with RAS inhibitors, despite their limited efficacy, possibly as a result of angiotensin escape and/or aldosterone escape, which leads to an escalation in renin activity subsequent to the prolonged inhibition of renin-angiotensin-aldosterone system (11). This evidence concerns the gene REN and diabetic kidney disease.